High‐quality trials and pharmacological studies needed as translational evidence for the application of traditional Chinese medicine Lianhua Qingwen against COVID‐19

Abstract

Traditional Chinese medicine (TCM) has been employed as complementary medication against COVID‐19 in China since 2020. Two years since then, TCM, with Lianhua Qingwen (LHQW) as an example, has been included in every version of official clinical protocol guidelines. Recently, LHQW is even distributed to general public at risk but not yet infected. Such common application and widely claimed positive outcome among mild to moderate patients were accompanied by a number of published studies on antiviral, antiinflammatory, and immune modulatory potential using either in vitro or animal models. However, aside from retrospective understanding and open‐labeled clinical trials with relatively small subject size, major gap in conclusive proof for efficacy and safety remains due to the lack of double‐blind placebo‐controlled studies and comprehensive pharmacodynamic and kinetic investigations. This is also supported by a recent WHO expert meeting on this subject, which acknowledged the potential benefits of TCM in mild–moderate cases, while recommended more rigorous studies to further understand effect size, application implications, and outcome determinants. Therefore, there is an urgent need to address the exact role TCM like LHQW could play in COVID‐19 management from translational evidence‐based perspective. High‐quality clinical trials, pharmacological studies, and real‐world data from recent outbreak are recommended.

Effect of Lianhua Qingwen capsules on the positive rate of COVID-19 close contacts: A retrospective analysis of a large-scale population-based cohort study

“…The approximate mortality rate from COVID-19 is 1%, which inevitably poses a substantial challenge to medical systems, especially the intensive care unit (ICU) capacity. Since the beginning of the epidemic, the global scientific community has made a rapid and robust response to uncover the clinical features and pathological process of COVID-19, including typical manifestations and multisystem inflammatory syndromes ( Hu et al, 2021 ; Huang and Li, 2022 ; Wiersinga et al, 2020 ). Yet, there are still no effective methods to treat COVID-19, i.e.,…”

An adventure from a work in progress: Challenges and opportunities of pharmacophylogeny in combat against COVID‐19

“…However, the new spikes of infection pose great challenges against national health care systems, and solely relying on COVID-19 vaccines is far less enough in the protecting immune-compromised population and reducing morbidity and mortality as much as possible. Herbal medicines could play an essential role in this respect (Huang & Li, 2022;Pagano, 2022). The National Administration of Traditional Chinese Medicine (TCM) and the administrative departments of TCM in provinces, regions, and cities have successively issued documents, such as TCM intervention guidelines and protection suggestions for COVID-19 infected persons at home (National Administration of TCM, 2022), advocating that health management and improving immunity can be conducted by means of herbal medicine prevention, air fumigation, epidemic prevention sachets, reasonable diet, fitness exercise, acupoint massage, regular daily living, and so forth.…”